Ho S. Lee

Busan, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 96 publications

Prospective, multicentre phase II study to evaluate the clinical benefit of reduced-dose lenalidomide and dexamethasone based on frailty stratification in elderly, unfit patients with newly diagnosed multiple myeloma.

Prospective, multicentre phase II study to evaluate the clinical benefit of reduced-dose lenalidomide and dexamethasone based on frailty stratification in elderly, unfit patients with newly diagnosed multiple myeloma.

Journal: British journal of haematology

Published: March 19, 2026

Longitudinal Whole-Exome Sequencing Identifies Clonal Hematopoiesis and Genomic Heterogeneity as a Predictor of Treatment Outcome in Patients with Newly Diagnosed, Elderly Chronic Lymphocytic Leukemia.

Longitudinal Whole-Exome Sequencing Identifies Clonal Hematopoiesis and Genomic Heterogeneity as a Predictor of Treatment Outcome in Patients with Newly Diagnosed, Elderly Chronic Lymphocytic Leukemia.

Journal: International journal of molecular sciences

Published: January 22, 2026

A multicentre prospective phase II study of rituximab combined with bortezomib, lenalidomide and dexamethasone, followed by lenalidomide maintenance (R-VRD) in patients with Waldenström's macroglobulinaemia (KMM1803).

A multicentre prospective phase II study of rituximab combined with bortezomib, lenalidomide and dexamethasone, followed by lenalidomide maintenance (R-VRD) in patients with Waldenström's macroglobulinaemia (KMM1803).

Journal: British journal of haematology

Published: September 01, 2025

Response kinetics as a dynamic prognostic marker in patients with multiple myeloma.

Response kinetics as a dynamic prognostic marker in patients with multiple myeloma.

Journal: Leukemia

Published: August 24, 2025

Correction: Evidence‑based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions.

Correction: Evidence‑based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions.

Journal: Blood research

Published: April 08, 2025

A comprehensive analysis of the role of stem cell transplantation in mantle cell lymphoma: real-world data from the Korean Society of Blood and Marrow Transplantation registry: Stem cell transplantation outcomes in mantle cell lymphoma.

A comprehensive analysis of the role of stem cell transplantation in mantle cell lymphoma: real-world data from the Korean Society of Blood and Marrow Transplantation registry: Stem cell transplantation outcomes in mantle cell lymphoma.

Journal: Blood research

Published: March 24, 2025

Efficacy, safety, and health-related quality of life in transplant-ineligible newly diagnosed multiple myeloma patients receiving bortezomib maintenance therapy: a study of the Korean Multiple Myeloma Working Party KMMWP-174 study.

Efficacy, safety, and health-related quality of life in transplant-ineligible newly diagnosed multiple myeloma patients receiving bortezomib maintenance therapy: a study of the Korean Multiple Myeloma Working Party KMMWP-174 study.

Journal: Haematologica

Published: March 22, 2025

Serial next-generation sequencing for detecting germline predisposition in acute myeloid leukemia.

Serial next-generation sequencing for detecting germline predisposition in acute myeloid leukemia.

Journal: Haematologica

Published: March 20, 2025

A Novel Squaramide Derivative, HR-19011, Induces the Integrated Stress Response via the HRI-eIF2α-ATF4 Pathway, Effectively Inhibiting Hematologic Malignancies.

A Novel Squaramide Derivative, HR-19011, Induces the Integrated Stress Response via the HRI-eIF2α-ATF4 Pathway, Effectively Inhibiting Hematologic Malignancies.

Journal: Molecular cancer therapeutics

Published: November 02, 2024

Evidence-based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions.

Evidence-based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions.

Journal: Blood research

Published: October 02, 2024

Comprehensive clinico-genetic analysis reveals prognostic factors of blastic plasmacytoid dendritic cell neoplasm.

Comprehensive clinico-genetic analysis reveals prognostic factors of blastic plasmacytoid dendritic cell neoplasm.

Journal: British journal of haematology

Published: September 23, 2024

Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: results of the multicenter KMMWP2201 study.

Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: results of the multicenter KMMWP2201 study.

Journal: Haematologica

Published: March 28, 2024

Showing 1-12 of 96

Last Updated: 09/26/2026